VEGI Antibody Recombinant Rabbit MAb / TL1A / TNFSF15 [clone TLRM1-2R] (V3785)

Catalog No.	Formulation	Size
V3785-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V3785-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V3785SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V3785IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml

Recombinant RABBIT MONOCLONAL

Bulk quote request

Species Reactivity	Human
Format	Purified
Host	Rabbit
Clonality	Recombinant Rabbit Monoclonal
Isotype	Rabbit IgG, kappa
Clone Name	TLRM1-2R
Purity	Protein A affinity chromatography
UniProt	O95150
Localization	Cytoplasmic, cell surface, secreted
Applications	Immunohistochemistry (FFPE) : 1-2ug/ml Prediluted IHC Only Format : incubate for 30 min at RT (1)
Limitations	This VEGI antibody is available for research use only.



Immunohistochemistry of VEGI antibody in human spleen tissue. FFPE human spleen shows cytoplasmic and membranous HRP-DAB brown staining within vascular endothelial and scattered stromal cell populations, consistent with Vascular endothelial growth inhibitor / TNFSF15 localization in immune and vascular compartments. Clone TLRM1-2R was used as a recombinant rabbit monoclonal antibody for detection. Heat-induced epitope retrieval was performed by boiling sections in 10 mM Tris with 1 mM EDTA, pH 9, for 10-20 minutes followed by cooling at room temperature for 20 minutes prior to staining.



Immunohistochemistry of VEGI antibody in human parathyroid mass tissue. FFPE human parathyroid lesion demonstrates diffuse cytoplasmic and membranous HRP-DAB brown staining within tumor cells, consistent with Vascular endothelial growth inhibitor / TNFSF15 expression in endocrine-associated tissue. Clone TLRM1-2R was used as a recombinant rabbit monoclonal antibody for detection. Heat-induced epitope retrieval was performed by boiling sections in 10 mM Tris with 1 mM EDTA, pH 9, for 10-20 minutes followed by cooling at room temperature for 20 minutes prior to staining.

Description

VEGI antibody recognizes Vascular endothelial growth inhibitor, a secreted cytokine encoded by the TNFSF15 gene and also known as TL1A. VEGI is a member of the tumor necrosis factor ligand superfamily and is primarily expressed by endothelial cells, where it regulates angiogenesis and immune signaling. VEGI Antibody Recombinant Rabbit MAb is developed to detect endogenous Vascular endothelial growth inhibitor in research applications focused on vascular biology and inflammatory pathways.

Vascular endothelial growth inhibitor functions as an anti-angiogenic factor that suppresses endothelial cell proliferation and modulates vascular remodeling. By binding to death receptor 3, also known as TNFRSF25, VEGI activates signaling pathways that influence apoptosis, cytokine production, and T cell activation. Through this receptor interaction, TNFSF15 contributes to immune regulation and maintenance of vascular homeostasis under both physiologic and inflammatory conditions.

The TNFSF15 gene is located on chromosome 9q32 and encodes a type II transmembrane protein that can be cleaved to generate a soluble form. VEGI expression is detected in vascular endothelium and certain immune cell populations, where it participates in modulation of inflammatory responses and lymphocyte differentiation. Dysregulated TNFSF15 signaling has been associated with inflammatory bowel disease, autoimmune disorders, and tumor biology, reflecting its dual role in angiogenesis control and immune activation.

In oncology research, VEGI has been studied for its capacity to inhibit tumor angiogenesis and limit tumor growth by reducing vascular support. In contrast, excessive or altered VEGI signaling may contribute to chronic inflammation in other disease settings. Because of its involvement in both vascular and immune pathways, Vascular endothelial growth inhibitor remains an important target in translational research.

Clone TLRM1-2R is a recombinant rabbit monoclonal antibody that recognizes VEGI and supports studies of TNFSF15-mediated signaling, angiogenic regulation, and immune pathway modulation.

Application Notes

The stated application concentrations are suggested starting points. Titration of the VEGI antibody may be required due to differences in protocols and secondary/substrate sensitivity.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

A full length human recombinant protein was used as the immunogen for this VEGI antibody.

Storage

Store the VEGI antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).